Special Populations

Paediatric Respiratory Reviews

Volumn 10, Issue SUPPL. 1, 2009, Pages 21-22

  Fauroux, Brigitte ^a  

^a ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

Bronchiolitis; High risk; Hospitalisation; Respiratory syncytial virus; RSV

Indexed keywords

PALIVIZUMAB;

ARTICLE; BRONCHIOLITIS; CHRONIC LUNG DISEASE; CONGENITAL HEART DISEASE; CYSTIC FIBROSIS; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; HIGH RISK INFANT; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; NEUROMUSCULAR DISEASE; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK FACTOR; VIRUS INFECTION;

AGE FACTORS; ANTIVIRAL AGENTS; BRONCHIOLITIS; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTORS;

EID: 67849117371     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/S1526-0542(09)70010-7     Document Type: Article

References (20)

1. Bosis S., Esposito S., Niesters H.G., et al. Role of respiratory pathogens in infants hospitalised for a first episode of wheezing and their impact on recurrences. Clin Microbiol Infect 14 (2008) 677-684
2. Leader S., and Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 143 5 Suppl (2003) S127-S132
3. Hall C.B., Weinberg G.A., Iwane M.K., et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 360 (2009) 588-598
4. Boyce T.G., Mellen B.G., Mitchel Jr. E.F., Wright P.F., and Griffin M.R. Rates of hospitalisation for respiratory syncytial virus infection among children in Medicaid. J Pediatr 137 (2000) 865-870
5. Stevens T.P., Sinkin R.A., Hall C.B., Maniscalco W.M., and McConnochie K.M. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalisation and economic implications of prophylaxis. Arch Pediatr Adolesc Med 154 (2000) 55-61
6. Liese J.G., Grill E., Fischer B., Roeckl-Wiedmann I., Carr D., and Belohradsky B.H. Incidence and risk factors of respiratory syncytial virus-related hospitalisations in premature infants in Germany. Eur J Pediatr 162 (2003) 230-236
7. Moler F.W., Khan A.S., Meliones J.N., Custer J.R., Palmisano J., and Shope T.C. Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. Crit Care Med 20 (1992) 1406-1413
8. Navas L., Wang E., de Carvalho V., and Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalised population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 121 (1992) 348-354
9. Buckingham S.C., Quasney M.W., Bush A.J., and DeVincenzo J.P. Respiratory syncytial virus infections in the pediatric intensive care unit: clinical characteristics and risk factors for adverse outcomes. Pediatr Crit Care Med 2 (2001) 318-323
10. Wilkesmann A., Ammann R.A., Schildgen O., et al. Hospitalised children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J 26 (2007) 485-491
11. Horn S.D., and Smout R.J. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 143 5 Suppl (2003) S133-S141
12. Giebels K., Marcotte J.E., Podoba J., et al. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol 43 (2008) 169-174
13. Van Ewijk B.E., Wolfs T.F., Aerts P.C., et al. RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr Res 61 (2007) 398-403
14. Ljungman P., Ward K.N., Crooks B.N., et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 28 (2001) 479-484
15. Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus (RSV) infection. Arch Dis Child 94 (2009) 99-103
16. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. Pediatrics 102 (1998) 531-537
17. Pedraz C., Carbonell-Estrany X., Figueras-Aloy J., and Quero J. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalisations in premature infants. Pediatr Infect Dis J 22 (2003) 823-827
18. Lacaze-Masmonteil T., Truffert P., Pinquier D., et al. Lower respiratory tract illness and RSV prophylaxis in very premature infants. Arch Dis Child 89 (2004) 562-567
19. Frogel M., Nerwen C., Boron M., Cohen A., et al. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry. Pediatr Infect Dis J 27 (2008) 870-873
20. Feltes T.F., Cabalka A.K., Meissner H.C., et al. Palivizumab prophylaxis reduces hospitalisation due to respiratory syncytial virus in young children with hemo-dynamically significant congenital heart disease. J Pediatr 143 (Oct 2003) 532-540